INO vs. RCEL, UTMD, ARAY, ANGO, TLSI, SGHT, PROF, LUNG, DRTS, and QIPT
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include AVITA Medical (RCEL), Utah Medical Products (UTMD), Accuray (ARAY), AngioDynamics (ANGO), TriSalus Life Sciences (TLSI), Sight Sciences (SGHT), Profound Medical (PROF), Pulmonx (LUNG), Alpha Tau Medical (DRTS), and Quipt Home Medical (QIPT). These companies are all part of the "surgical & medical instruments" industry.
Inovio Pharmaceuticals (NASDAQ:INO) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of AVITA Medical shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of AVITA Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Inovio Pharmaceuticals received 644 more outperform votes than AVITA Medical when rated by MarketBeat users. Likewise, 71.46% of users gave Inovio Pharmaceuticals an outperform vote while only 68.57% of users gave AVITA Medical an outperform vote.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than AVITA Medical. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 2 mentions for AVITA Medical. AVITA Medical's average media sentiment score of 0.42 beat Inovio Pharmaceuticals' score of -0.01 indicating that AVITA Medical is being referred to more favorably in the news media.
Inovio Pharmaceuticals presently has a consensus target price of $96.00, suggesting a potential upside of 808.23%. AVITA Medical has a consensus target price of $27.80, suggesting a potential upside of 226.29%. Given Inovio Pharmaceuticals' higher probable upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than AVITA Medical.
AVITA Medical has a net margin of -70.56% compared to Inovio Pharmaceuticals' net margin of -16,238.91%. AVITA Medical's return on equity of -54.80% beat Inovio Pharmaceuticals' return on equity.
Inovio Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
AVITA Medical has higher revenue and earnings than Inovio Pharmaceuticals. AVITA Medical is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
AVITA Medical beats Inovio Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
